X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs LUPIN LTD - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH LUPIN LTD PANACEA BIOTECH/
LUPIN LTD
 
P/E (TTM) x 83.9 16.4 511.6% View Chart
P/BV x 1.9 3.8 48.8% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 PANACEA BIOTECH   LUPIN LTD
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
LUPIN LTD
Mar-16
PANACEA BIOTECH/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1492,127 7.0%   
Low Rs821,294 6.4%   
Sales per share (Unadj.) Rs84.1304.1 27.7%  
Earnings per share (Unadj.) Rs-18.350.4 -36.3%  
Cash flow per share (Unadj.) Rs-6.760.7 -11.0%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs83.7243.8 34.3%  
Shares outstanding (eoy) m61.25450.58 13.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.45.6 24.4%   
Avg P/E ratio x-6.333.9 -18.6%  
P/CF ratio (eoy) x-17.228.2 -61.2%  
Price / Book Value ratio x1.47.0 19.7%  
Dividend payout %014.9 0.0%   
Avg Mkt Cap Rs m7,074770,740 0.9%   
No. of employees `0002.816.4 16.8%   
Total wages/salary Rs m1,44921,077 6.9%   
Avg. sales/employee Rs Th1,874.18,379.6 22.4%   
Avg. wages/employee Rs Th527.01,289.0 40.9%   
Avg. net profit/employee Rs Th-407.71,388.7 -29.4%   
INCOME DATA
Net Sales Rs m5,154137,016 3.8%  
Other income Rs m1001,877 5.3%   
Total revenues Rs m5,254138,893 3.8%   
Gross profit Rs m-76637,535 -2.0%  
Depreciation Rs m7114,635 15.3%   
Interest Rs m1,503446 336.8%   
Profit before tax Rs m-2,88134,330 -8.4%   
Minority Interest Rs m11-88 -12.3%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m1711,536 0.1%   
Profit after tax Rs m-1,12122,707 -4.9%  
Gross profit margin %-14.927.4 -54.3%  
Effective tax rate %-0.633.6 -1.7%   
Net profit margin %-21.816.6 -131.3%  
BALANCE SHEET DATA
Current assets Rs m3,81097,790 3.9%   
Current liabilities Rs m8,36553,872 15.5%   
Net working cap to sales %-88.432.1 -275.7%  
Current ratio x0.51.8 25.1%  
Inventory Days Days15685 183.8%  
Debtors Days Days67121 55.5%  
Net fixed assets Rs m14,48086,379 16.8%   
Share capital Rs m61901 6.8%   
"Free" reserves Rs m903105,735 0.9%   
Net worth Rs m5,127109,844 4.7%   
Long term debt Rs m5,83253,739 10.9%   
Total assets Rs m19,433224,378 8.7%  
Interest coverage x-0.977.9 -1.2%   
Debt to equity ratio x1.10.5 232.5%  
Sales to assets ratio x0.30.6 43.4%   
Return on assets %2.010.3 19.0%  
Return on equity %-21.920.7 -105.8%  
Return on capital %3.621.2 17.1%  
Exports to sales %24.549.1 50.0%   
Imports to sales %10.27.4 136.8%   
Exports (fob) Rs m1,26467,244 1.9%   
Imports (cif) Rs m52510,199 5.1%   
Fx inflow Rs m1,53971,405 2.2%   
Fx outflow Rs m94217,807 5.3%   
Net fx Rs m59753,598 1.1%   
CASH FLOW
From Operations Rs m599-3,690 -16.2%  
From Investments Rs m-438-69,434 0.6%  
From Financial Activity Rs m-30358,126 -0.5%  
Net Cashflow Rs m-141-14,998 0.9%  

Share Holding

Indian Promoters % 74.5 46.6 159.9%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.6 11.3 5.3%  
FIIs % 1.3 31.9 4.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.1 233.7%  
Shareholders   10,259 98,259 10.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare PANACEA BIOTECH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Lower; IT Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the IT sector and power sector witnessing maximum selling pressure.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 21, 2017 12:07 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - ALKEM LABORATORIES COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS